Back to Peptides
Fat LossHigh Risk

Tesamorelin

Also known as: Egrifta, TH9507

Half-life:
26–38 minutes

Administration Routes

subcutaneous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.

Tesamorelin is a stabilised analogue of endogenous growth hormone-releasing hormone (GHRH). It holds FDA approval for the treatment of HIV-associated lipodystrophy and is the most clinically studied GHRH analogue. Outside its approved indication, it is researched for visceral fat reduction, cognitive function, and metabolic health in older adults.

Primary Research Areas

  • fat_loss
  • longevity

Risk Profile

High Risk

Higher risk profile in research contexts. Consult a healthcare professional before use.

Providers Offering Tesamorelin